Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.21
+0.35001.41%
Volume:76.87K
Turnover:1.92M
Market Cap:1.00B
PE:71.67
High:25.21
Open:24.89
Low:24.80
Close:24.86
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:0.38
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.50
PE(LYR):159.73

Loading ...

Doma Perpetual nominates three to Pacira board

TIPRANKS
·
Mar 12

DOMA Perpetual nominates three directors for Pacira board after taking 7.1% stake

Reuters
·
Mar 12

Doma Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira Biosciences, Inc.

THOMSON REUTERS
·
Mar 12

Doma Perpetual Capital Management: Believes Board Must Avoid Taking Any Further Risk With Ip Battles

THOMSON REUTERS
·
Mar 12

Doma Perpetual Capital Management- Calls for Immediate Replacement of CEO Frank Lee and Conduct Formal Sale Process

THOMSON REUTERS
·
Mar 12

BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 06

Pacira BioSciences Reports Inducement Equity Grants to New Employees

Reuters
·
Mar 06

Pacira BioSciences to Join Analyst-Led Fireside Chat at Barclays Global Healthcare Conference

Reuters
·
Mar 04

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Harrow Health (HROW)

TIPRANKS
·
Mar 03

Pacira Presents IGOR Real-World Studies Highlighting EXPAREL and iovera Knee Pain Benefits at AAOS 2026

Reuters
·
Mar 02

Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple

Simply Wall St.
·
Mar 01

Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating

MT Newswires Live
·
Feb 27

Truist Financial Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
Feb 27

BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results

Reuters
·
Feb 27

Pacira BioSciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $196.873M Miss $200.424M Estimate.

Benzinga Earnings
·
Feb 27

BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million

Reuters
·
Feb 27

Pacira Biosciences Inc - Outlook 2026 Total Revenue of $745 Million to $770 Millionmln

THOMSON REUTERS
·
Feb 27

Pacira Biosciences Q4 Adj EPS $0.57; Q4 REV $196.9 Mln

THOMSON REUTERS
·
Feb 27

Pacira Biosciences - Outlook FY Total Revenue $745 Million to $770 Million

THOMSON REUTERS
·
Feb 27